Solius Labs raises $23M in Series A

Solius Labs, based in Bainbridge Island, Washington, has raised $23 million in a Series A funding round. The capital injection is earmarked to support the launch of the Solius Pro, a UVB light therapy device for home and professional use. This development underscores Solius's strategic pivot from larger kiosk-based systems to compact, wall-mounted devices intended for broader consumer and clinical use.

The Series A round was led by Lauder Partners and comprised contributions from venture capital funds, family offices, and individual investors. The $2,995 Solius Pro, recently cleared by the FDA as a Class II medical device, delivers a personalized UVB light dose to stimulate vitamin D production. Utilizing a patent-pending skin scanner, the device calculates the appropriate wavelength for each user's skin type, ensuring safety and efficacy. Solius has already registered over 1,000 pre-orders ahead of its official launch, with initial shipments set to commence in July.

Solius, founded in 2013, has transitioned from light therapy kiosks used in pharmacies and clinical trials to this more accessible technology. Under the leadership of CEO Kiple, who took the helm in 2023, the company has refocused its strategy towards creating more affordable solutions for both consumers and professionals. Kiple's team, recruited from Ventec Life Systems, emphasizes the potential market reach from home users to healthcare and wellness centers.

This fundraising and product launch emerge as vitamin D deficiency is recognized as a significant global health issue, affecting an estimated one billion people worldwide. The condition is linked to various health concerns, including seasonal affective disorder and bone density loss. Solius Pro aims to address these issues by offering a convenient way to replicate sunlight exposure, which is particularly relevant in regions with limited sunshine, such as the Pacific Northwest.

Moving forward, Solius Labs is focused on scaling production and expanding its workforce, with active recruitment across engineering, quality, sales, and marketing functions. With FDA clearance secured, the company’s next milestones include successful market penetration and potential further enhancements of its technology to continue addressing diverse health needs.